Form D · Biotechnology
Janux Therapeutics, Inc.
La Jolla, CA · CIK 0001817713
Offering snapshot reported Apr 30, 2021 · SEC filing
- Reported sold
- $125M Offering amount: $125M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 15, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 30, 2021 | Initial | $125,000,073 | No comparison | 22 | SEC filing |
| Mar 12, 2021 | Initial | $56,000,030 | No comparison | 7 | SEC filing |
| Jul 14, 2020 | Initial | $11,439,224 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-397786
Source: Form D, filed Apr 30, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Campbell, Ph.D. | Director, Executive |
| Vickie L. Capps | Director |
| Sheila Gujrathi | Director |
| Stefan Heller | Director |
| Jay Lichter, Ph.D. | Director |
| Tighe Reardon | Executive |
| Jake Simson, Ph.D. | Director |
| Peter Thompson, M.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
11099 Torrey Pines Road
La Jolla, CA, 92037
La Jolla, CA, 92037